Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Long-Term Investments (2017 - 2025)

Anaptysbio filings provide 9 years of Long-Term Investments readings, the most recent being $7.7 million for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Investments fell 72.42% year-over-year to $7.7 million, compared with a TTM value of $7.7 million through Sep 2025, down 72.42%, and an annual FY2024 reading of $35.5 million, up 31.24% over the prior year.
  • Long-Term Investments hit $7.7 million in Q3 2025 for Anaptysbio, down from $28.0 million in the prior quarter.
  • The five-year high for Long-Term Investments was $147.5 million in Q3 2022, with the low at $5.5 million in Q2 2021.
  • Median Long-Term Investments over the past 5 years was $40.2 million (2023), compared with a mean of $54.1 million.
  • The sharpest move saw Long-Term Investments tumbled 85.95% in 2021, then soared 2270.26% in 2022.
  • Year by year, Long-Term Investments stood at $67.1 million in 2021, then skyrocketed by 113.03% to $142.9 million in 2022, then crashed by 81.09% to $27.0 million in 2023, then skyrocketed by 31.24% to $35.5 million in 2024, then tumbled by 78.3% to $7.7 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $7.7 million, $28.0 million, and $43.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.